Tag: tumorSize

News

12/07/21

Breast cancer characteristics that increase likelihood of late recurrence

05/12/21

Tamoxifen increases long-term survival in women with large tumor size

11/18/17

Late recurrence of ER+ BC linked to primary tumor characteristics

10/18/15

Late recurrence of ER+ breast cancer is more likely for some women

03/22/15

Type 2 diabetes is linked to higher breast cancer stage at diagnosis

01/20/13

Some BC types have up to 11% locoregional recurrence after mastectomy

08/12/12

Lymph node negative ER-/PR- BC has less favorable prognosis

06/25/12

Lobular breast cancer has less favorable prognosis than expected

06/20/12

Large breast size linked to reduced survival for ER+ breast cancer

04/12/12

Five-year prognosis by breast cancer subtype

06/24/11

Multifocal breast cancer has worse prognosis than single tumors

05/28/11

Triple negative prognosis is influenced by number of positive nodes

11/30/10

Small triple negative tumors have worse prognosis than small ER+/PR+

Studies

• Expression of Ki-67 in Invasive Breast Carcinoma and Its Correlation With Different Clinicopathological Features Cite
  Sandilya U, K M. Expression of Ki-67 in Invasive Breast Carcinoma and Its Correlation With Different Clinicopathological Features. Cureus. Springer Science and Business Media LLC; 2024; 10.7759/cureus.69820
• The association between dietary acid load index with tumor stage and size, histological grade, Ki-67 marker, and the odds of breast cancer: A case-control study based on hospital evidence Cite
  Khodabakhshi A, Nasab SAR, Rafeeinia A, Hesami S, Bazyar H, Aghamohammadi V. The association between dietary acid load index with tumor stage and size, histological grade, Ki-67 marker, and the odds of breast cancer: A case-control study based on hospital evidence. Springer Science and Business Media LLC; 2024; 10.21203/rs.3.rs-4873761/v1
• The association between infectious agents and breast cancer: a review of the epidemiologic evidence Cite
  Brantley KD, Tamimi RM. The association between infectious agents and breast cancer: a review of the epidemiologic evidence. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2024; 10.1007/s10549-024-07388-6
• Clinical and molecular predictors of very late recurrence in oestrogen receptor-positive breast cancer patients Cite
  Richman J, Schuster G, Buus R, Lopez-Knowles E, Dowsett M. Clinical and molecular predictors of very late recurrence in oestrogen receptor-positive breast cancer patients. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2024; 10.1007/s10549-024-07311-z
• Invasive lobular carcinoma of the breast; clinicopathologic profile and response to neoadjuvant chemotherapy over a 15-year period Cite
  Quirke N, Cullinane C, Turk M, Shafique N, Evoy D, Geraghty J, et al. Invasive lobular carcinoma of the breast; clinicopathologic profile and response to neoadjuvant chemotherapy over a 15-year period. The Breast. Elsevier BV; 2024;:103739 10.1016/j.breast.2024.103739
• Lumpectomy without radiation for ductal carcinoma in situ of the breast: 20-year results from the ECOG-ACRIN E5194 study Cite
  Wright JL, Gray R, Rahbar H, Comstock CE, Tjoe JA, Badve S, et al. Lumpectomy without radiation for ductal carcinoma in situ of the breast: 20-year results from the ECOG-ACRIN E5194 study. npj Breast Cancer. Springer Science and Business Media LLC; 2024; 10 10.1038/s41523-024-00622-w
• Potential interplay between tumor size and vitamin D receptor (VDR) polymorphisms in breast cancer prognosis: a prospective cohort study Cite
  Lindgren H, Ademi D, Godina C, Tryggvadottir H, Isaksson K, Jernström H. Potential interplay between tumor size and vitamin D receptor (VDR) polymorphisms in breast cancer prognosis: a prospective cohort study. Cancer Causes & Control. Springer Science and Business Media LLC; 2024; 10.1007/s10552-023-01845-1
• Predictors of Early Versus Late Recurrence in Invasive Lobular Carcinoma of the Breast: Impact of Local and Systemic Therapy Cite
  Rothschild HT, Clelland EN, Mujir F, Record H, Wong J, Esserman LJ, et al. Predictors of Early Versus Late Recurrence in Invasive Lobular Carcinoma of the Breast: Impact of Local and Systemic Therapy. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2023; 30:5999-6006 10.1245/s10434-023-13881-x
• Tumor Characteristics of Bilateral Breast Cancer Compared with Unilateral Breast Cancer Cite
  Schulze AK, Hoskin TL, Moldoveanu D, Sturz JL, Boughey JC. Tumor Characteristics of Bilateral Breast Cancer Compared with Unilateral Breast Cancer. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2023; 10.1245/s10434-023-14451-x
• Survival After Contralateral Secondary Breast Cancer by Age Group in California Cite
  Perry LM, Keegan THM, Li Q, Bold RJ, Antonino NF, Maguire FB, et al. Survival After Contralateral Secondary Breast Cancer by Age Group in California. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2023; 10.1245/s10434-023-13902-9
• Predictive biological factors for late survival in patients with HER2-positive breast cancer Cite
  Kang Y, Oh SJ, Bae SY, Kim E, Lee Y, Park EH, et al. Predictive biological factors for late survival in patients with HER2-positive breast cancer. Scientific Reports. Springer Science and Business Media LLC; 2023; 13 10.1038/s41598-023-38200-y
• Breast cancer mortality in 500 000 women with early invasive breast cancer in England, 1993-2015: population based observational cohort study Cite
  Taylor C, McGale P, Probert J, Broggio J, Charman J, Darby SC, et al. Breast cancer mortality in 500 000 women with early invasive breast cancer in England, 1993-2015: population based observational cohort study. BMJ. BMJ; 2023;:e074684 10.1136/bmj-2022-074684
• Epstein-Barr virus in breast carcinoma and in triple negative cases impact on clinical outcomes Cite
  Mekrazi S, Kallel I, Jamai D, Yengui M, Khabir A, Gdoura R. Epstein-Barr virus in breast carcinoma and in triple negative cases impact on clinical outcomes. Pathology - Research and Practice. Elsevier BV; 2023; 245:154484 10.1016/j.prp.2023.154484
• Prognosis after Local Recurrence in Patients with Early-Stage Breast Cancer Treated without Chemotherapy Cite
  Sopik V, Lim D, Sun P, Narod SA. Prognosis after Local Recurrence in Patients with Early-Stage Breast Cancer Treated without Chemotherapy. Current Oncology. MDPI AG; 2023; 30:3829-3844 10.3390/curroncol30040290
• Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy—a sub-analysis of the ALTTO study Cite
  Nader-Marta G, Debien V, Eiger D, Tsourti Z, Caparica R, Kassapian M, et al. Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy—a sub-analysis of the ALTTO study. British Journal of Cancer. Springer Science and Business Media LLC; 2022; 127:1799-1807 10.1038/s41416-022-01963-8
• Low baseline vitamin D levels correlate with adverse pathological features and clinical outcomes among patients with breast cancer. Cite
  Barakat D, Mohamed R, Elnaggar M, Tarik D, Eid SM. Low baseline vitamin D levels correlate with adverse pathological features and clinical outcomes among patients with breast cancer.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2022; 40:552-552 10.1200/jco.2022.40.16_suppl.552
• A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer Cite
  Sheffield KM, Peachey JR, Method M, Grimes BR, Brown J, Saverno K, et al. A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer. Future Oncology. Future Medicine Ltd; 2022; 10.2217/fon-2022-0310
• Impact of Diabetes on Patient Outcomes in Breast Cancer Patients Cite
  Tobe A, Horimoto Y, Kobayashi K, Kamisada N, Hirano M. Impact of Diabetes on Patient Outcomes in Breast Cancer Patients. Breast Care. S. Karger AG; 2022; 10.1159/000524513
• Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review Cite
  Garutti M, Griguolo G, Botticelli A, Buzzatti G, De Angelis C, Gerratana L, et al. Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review. Cancers. MDPI AG; 2022; 14:1898 10.3390/cancers14081898
• The association between the inflammatory potential of diet and the risk of histopathological and molecular subtypes of breast cancer in northwestern Iran: Results from the Breast Cancer Risk and Lifestyle study Cite
  Hayati Z, Montazeri V, Shivappa N, Hebert JR, Pirouzpanah S. The association between the inflammatory potential of diet and the risk of histopathological and molecular subtypes of breast cancer in northwestern Iran: Results from the Breast Cancer Risk and Lifestyle study. Cancer. Wiley; 2022; 10.1002/cncr.34183
• Higher risk tumor features are not associated with higher nodal stage in patients with estrogen receptor-positive, node-positive breast cancer Cite
  Ye L, Rünger D, Angarita SA, Hadaya J, Baker JL, Lee MK, et al. Higher risk tumor features are not associated with higher nodal stage in patients with estrogen receptor-positive, node-positive breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2022; 10.1007/s10549-022-06581-9
• Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics Cite
  Nelson DR, Brown J, Morikawa A, Method M. Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics. PLOS ONE. Public Library of Science (PLoS); 2022; 17:e0264637 10.1371/journal.pone.0264637
• Long-term outcomes of women with large DCIS lesions treated with breast-conserving therapy Cite
  Rodin D, Sutradhar R, Nofech-Mozes S, Gu S, Faught N, Hahn E, et al. Long-term outcomes of women with large DCIS lesions treated with breast-conserving therapy. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2022; 10.1007/s10549-021-06488-x
• Ductal carcinoma in situ: a risk prediction model for the underestimation of invasive breast cancer Cite
  Park KW, Kim SW, Han H, Park M, Han B, Ko EY, et al. Ductal carcinoma in situ: a risk prediction model for the underestimation of invasive breast cancer. npj Breast Cancer. Springer Science and Business Media LLC; 2022; 8 10.1038/s41523-021-00364-z
• The Incidence of Breast Cancer Recurrence 10-32 Years after Primary Diagnosis Cite
  Pedersen RN, Esen BÖ, Mellemkjær L, Christiansen P, Ejlertsen B, Lash TL, et al. The Incidence of Breast Cancer Recurrence 10-32 Years after Primary Diagnosis. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2021; 10.1093/jnci/djab202
• Association Between Metabolic Syndrome and Immunohistochemical Profile at Breast Cancer Diagnosis in Postmenopausal Women Cite
  Motoki AH, Buttros DA, Gaspar AL, Almeida-Filho BS, Carvalho-Pessoa E, Vespoli HD, et al. Association Between Metabolic Syndrome and Immunohistochemical Profile at Breast Cancer Diagnosis in Postmenopausal Women. Clinical Breast Cancer. Elsevier BV; 2021; 10.1016/j.clbc.2021.07.009
• Associations of hair dye and relaxer use with breast tumor clinicopathologic features: Findings from the Women’s circle of Health Study Cite
  Rao R, McDonald JA, Barrett ES, Greenberg P, Teteh DK, Montgomery SB, et al. Associations of hair dye and relaxer use with breast tumor clinicopathologic features: Findings from the Women’s circle of Health Study. Environmental Research. Elsevier BV; 2022; 203:111863 10.1016/j.envres.2021.111863
• The Effect of Body Mass Index on Initial Breast Cancer Stage Among Korean Women Cite
  Lee Y, Kang E, Shin H, Lee H, Yoon K, Kang B, et al. The Effect of Body Mass Index on Initial Breast Cancer Stage Among Korean Women. Clinical Breast Cancer. Elsevier BV; 2021; 10.1016/j.clbc.2021.04.007
• Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression Cite
  Pellegrino B, Hlavata Z, Migali C, De Silva P, Aiello M, Willard-Gallo K, et al. Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression. Molecular Diagnosis & Therapy. Springer Science and Business Media LLC; 2021; 10.1007/s40291-021-00525-7
• 6P 25-year survival and benefit from tamoxifen therapy by the clinically used breast cancer markers in lymph node-negative and ER-positive/HER2-negative breast cancer Cite
  Dar H, Johansson A, Nordensköljd A, Iftimi A, Yau C, Perez-Tenorio G, et al. 6P 25-year survival and benefit from tamoxifen therapy by the clinically used breast cancer markers in lymph node-negative and ER-positive/HER2-negative breast cancer. Annals of Oncology. Elsevier BV; 2021; 32:S23 10.1016/j.annonc.2021.03.020
• Total long-chain polyunsaturated n-3 fatty acids level is an independent predictive factor of breast cancer multifocality in women with positive hormone-receptors tumors Cite
  Ouldamer L, Goupille C, Vildé A, Arbion F, Guimaraes C, Jourdan M, et al. Total long-chain polyunsaturated n-3 fatty acids level is an independent predictive factor of breast cancer multifocality in women with positive hormone-receptors tumors. Surgical Oncology. Elsevier BV; 2021;:101597 10.1016/j.suronc.2021.101597
• Positive estrogen receptor status is a poor prognostic factor in node-negative breast cancer Cite
  Jung EJ, Kim J, Kim J, Lee HS, Kwag S, Park J, et al. Positive estrogen receptor status is a poor prognostic factor in node-negative breast cancer. Medicine. Ovid Technologies (Wolters Kluwer Health); 2021; 100:e25000 10.1097/md.0000000000025000
• HER2 intratumoral heterogeneity is independently associated with distal metastasis and overall survival in HER2-positive breast carcinomas Cite
  Shen T, Nitta H, Wei L, Parwani AV, Li Z. HER2 intratumoral heterogeneity is independently associated with distal metastasis and overall survival in HER2-positive breast carcinomas. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 181:519-527 10.1007/s10549-020-05650-1
• Clinical behavior of recurrent hormone receptor–positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1‐98 clinical trial Cite
  Leone JP, Cole BF, Regan MM, Thürlimann B, Coates AS, Rabaglio M, et al. Clinical behavior of recurrent hormone receptor–positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1‐98 clinical trial. Cancer. Wiley; 2020; 10.1002/cncr.33318
• Predicting the Survival of Triple-Negative Breast Cancer in Different Stages: A SEER Population Based Research Referring to Clinicopathological Factors Cite
  Chen S, Tang S, Li K, Wu J, Li X, Ren H, et al. Predicting the Survival of Triple-Negative Breast Cancer in Different Stages: A SEER Population Based Research Referring to Clinicopathological Factors. Cancer Investigation. Informa UK Limited; 2020; 38:549-558 10.1080/07357907.2020.1831010
• Do Obese Patients Present With More Advanced Breast Cancer? Cite
  Wang M, Huang J, Chagpar AB. Do Obese Patients Present With More Advanced Breast Cancer?. The American Surgeon. SAGE Publications; 2020;:000313482094951 10.1177/0003134820949510
• Breast cancer in women younger than 35 years old Cite
  Zouzoulas D, Tsolakidis D, Gitas G, Zafrakas M, Goulis DG, Douganiotis G, et al. Breast cancer in women younger than 35 years old. Archives of Gynecology and Obstetrics. Springer Science and Business Media LLC; 2020; 302:721-730 10.1007/s00404-020-05695-z
• Tumour characteristics and survivorship in a cohort of breast cancer: the MCC-Spain study Cite
  Gómez-Acebo I, Dierssen-Sotos T, Palazuelos-Calderón C, Pérez-Gómez B, Amiano P, Guevara M, et al. Tumour characteristics and survivorship in a cohort of breast cancer: the MCC-Spain study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 181:667-678 10.1007/s10549-020-05600-x
• Breast Cancer in Young Women Presents With More Aggressive Pathologic Characteristics: Retrospective Analysis From an Argentine National Database Cite
  Fabiano V, Mandó P, Rizzo M, Ponce C, Coló F, Loza M, et al. Breast Cancer in Young Women Presents With More Aggressive Pathologic Characteristics: Retrospective Analysis From an Argentine National Database. JCO Global Oncology. American Society of Clinical Oncology (ASCO); 2020;:639-646 10.1200/jgo.19.00228
• Long-term Results After Neoadjuvant Chemotherapy for Breast Cancer: A Single-center Experience Cite
  GIANI M, RENDA I, VALLARIO A, TAVELLA K, VILLANUCCI A, NORI J, et al. Long-term Results After Neoadjuvant Chemotherapy for Breast Cancer: A Single-center Experience. Anticancer Research. Anticancer Research USA Inc.; 2020; 40:1079-1085 10.21873/anticanres.14046
• Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence Cite
  Conforti F, Pala L, Pagan E, Viale G, Bagnardi V, Peruzzotti G, et al. Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence. Breast Cancer Research. Springer Science and Business Media LLC; 2019; 21 10.1186/s13058-019-1234-9
• Clinical and pathological predictors of recurrence in breast cancer patients achieving pathological complete response to neoadjuvant chemotherapy Cite
  Asaoka M, Narui K, Suganuma N, Chishima T, Yamada A, Sugae S, et al. Clinical and pathological predictors of recurrence in breast cancer patients achieving pathological complete response to neoadjuvant chemotherapy. European Journal of Surgical Oncology. Elsevier BV; 2019; 45:2289-2294 10.1016/j.ejso.2019.08.001
• Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials Cite
  Qian X, Li Z, Ruan G, Tu C, Ding W. Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2019; 179:275-285 10.1007/s10549-019-05464-w
• Adjuvant Radiation Therapy for T3N0 Breast Cancer Patients Older Than 75 Years After Mastectomy: A SEER Analysis Cite
  Chen J, Wu X, Christos P, Yan W, Ravi A. Adjuvant Radiation Therapy for T3N0 Breast Cancer Patients Older Than 75 Years After Mastectomy: A SEER Analysis. Clinical Breast Cancer. Elsevier BV; 2018; 18:e967-e973 10.1016/j.clbc.2018.05.002
• The relationship between patient and tumor characteristics, patterns of breast cancer care, and 5-year survival among elderly women with incident breast cancer Cite
  Kong AL, Nattinger AB, McGinley E, Pezzin LE. The relationship between patient and tumor characteristics, patterns of breast cancer care, and 5-year survival among elderly women with incident breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 171:477-488 10.1007/s10549-018-4837-4
• The relationship between tumour size, nodal status and distant metastases: on the origins of breast cancer Cite
  Sopik V, Narod SA. The relationship between tumour size, nodal status and distant metastases: on the origins of breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 170:647-656 10.1007/s10549-018-4796-9
• Treatment Outcomes in Male Breast Cancer: A Retrospective Analysis of 161 Patients Cite
  Wan B, Ganesh V, Zhang L, Sousa P, Drost L, Lorentz J, et al. Treatment Outcomes in Male Breast Cancer: A Retrospective Analysis of 161 Patients. Clinical Oncology. Elsevier BV; 2018; 30:354-365 10.1016/j.clon.2018.02.026
• Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients Cite
  Chen R, Ye Y, Yang C, Peng Y, Zong B, Qu F, et al. Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 170:35-43 10.1007/s10549-018-4730-1
• Factors associated with breast cancer recurrences or mortality and dynamic prediction of death using history of cancer recurrences: the French E3N cohort Cite
  Lafourcade A, His M, Baglietto L, Boutron-Ruault M, Dossus L, Rondeau V. Factors associated with breast cancer recurrences or mortality and dynamic prediction of death using history of cancer recurrences: the French E3N cohort. BMC Cancer. Springer Science and Business Media LLC; 2018; 18 10.1186/s12885-018-4076-4
• Metastasis-free interval in breast cancer patients: Thirty-year trends and time dependency of prognostic factors. A retrospective analysis based on a single institution experience Cite
  Houzé de l’Aulnoit A, Rogoz B, Pinçon C, Houzé de l’Aulnoit D. Metastasis-free interval in breast cancer patients: Thirty-year trends and time dependency of prognostic factors. A retrospective analysis based on a single institution experience. The Breast. Elsevier BV; 2018; 37:80-88 10.1016/j.breast.2017.10.008
• The prognostic role of tumor size in early breast cancer in the era of molecular biology Cite
  Kasangian AA, Gherardi G, Biagioli E, Torri V, Moretti A, Bernardin E, et al. The prognostic role of tumor size in early breast cancer in the era of molecular biology. PLOS ONE. Public Library of Science (PLoS); 2017; 12:e0189127 10.1371/journal.pone.0189127
• 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years Cite
  Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, et al. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. New England Journal of Medicine. Massachusetts Medical Society; 2017; 377:1836-1846 10.1056/nejmoa1701830
• Breast cancer in elderly women and altered clinico-pathological characteristics: a systematic review Cite
  Lodi M, Scheer L, Reix N, Heitz D, Carin A, Thiébaut N, et al. Breast cancer in elderly women and altered clinico-pathological characteristics: a systematic review. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 166:657-668 10.1007/s10549-017-4448-5
• Risk of death from breast cancer after treatment for ductal carcinoma in situ Cite
  Wadsten C, Garmo H, Fredriksson I, Sund M, Wärnberg F. Risk of death from breast cancer after treatment for ductal carcinoma in situ. British Journal of Surgery. Oxford University Press (OUP); 2017; 104:1506-1513 10.1002/bjs.10589
• Patterns and predictors of first and subsequent recurrence in women with early breast cancer Cite
  Geurts YM, Witteveen A, Bretveld R, Poortmans PM, Sonke GS, Strobbe LJA, et al. Patterns and predictors of first and subsequent recurrence in women with early breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 165:709-720 10.1007/s10549-017-4340-3
• Factors Associated with Recurrence Rates and Long-Term Survival in Women Diagnosed with Breast Cancer Ages 40 and Younger Cite
  Plichta JK, Rai U, Tang R, Coopey SB, Buckley JM, Gadd MA, et al. Factors Associated with Recurrence Rates and Long-Term Survival in Women Diagnosed with Breast Cancer Ages 40 and Younger. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2016; 23:3212-3220 10.1245/s10434-016-5404-z
• Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer Cite
  Lee E, Han W, Kim MK, Kim J, Yoo T, Lee MH, et al. Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer. BMC Cancer. Springer Science and Business Media LLC; 2016; 16 10.1186/s12885-016-2423-x
• Effect of nodal status on clinical outcomes of triple-negative breast cancer: a population-based study using the SEER 18 database Cite
  Wang X, Jiang Y, Li J, Song C, Shao Z. Effect of nodal status on clinical outcomes of triple-negative breast cancer: a population-based study using the SEER 18 database. Oncotarget. Impact Journals, LLC; 2016; 7:46636-46645 10.18632/oncotarget.9432
• Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy Cite
  Baron P, Beitsch P, Boselli D, Symanowski J, Pellicane JV, Beatty J, et al. Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2015; 23:1522-1529 10.1245/s10434-015-5030-1
• Premenopausal Obesity and Breast Cancer Growth Rates in a Rodent Model Cite
  Matthews S, McGinley J, Neil E, Thompson H. Premenopausal Obesity and Breast Cancer Growth Rates in a Rodent Model. Nutrients. MDPI AG; 2016; 8:214 10.3390/nu8040214
• Breast conservation after neoadjuvant therapy for tumors ≥5 cm: A prospective cohort study Cite
  Libson S, Koshenkov V, Rodgers S, Hurley J, Avisar E. Breast conservation after neoadjuvant therapy for tumors ≥5 cm: A prospective cohort study. International Journal of Surgery Open. Elsevier BV; 2015; 1:10-13 10.1016/j.ijso.2015.12.001
• Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer Cite
  Yamashita H, Ogiya A, Shien T, Horimoto Y, Masuda N, Inao T, et al. Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer. Breast Cancer. Springer Science and Business Media LLC; 2015; 23:830-843 10.1007/s12282-015-0649-0
• Influence of tumour stage at breast cancer detection on survival in modern times: population based study in 173 797 patients Cite
  Saadatmand S, Bretveld R, Siesling S, Tilanus-Linthorst MMA. Influence of tumour stage at breast cancer detection on survival in modern times: population based study in 173 797 patients. BMJ. BMJ; 2015;:h4901 10.1136/bmj.h4901
• Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer Cite
  Farolfi A, Scarpi E, Rocca A, Mangia A, Biglia N, Gianni L, et al. Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer. European Journal of Cancer. Elsevier BV; 2015; 51:1874-1881 10.1016/j.ejca.2015.07.003
• Improvements in US Breast Cancer Survival and Proportion Explained by Tumor Size and Estrogen-Receptor Status Cite
  Park J, Anderson WF, Gail MH. Improvements in US Breast Cancer Survival and Proportion Explained by Tumor Size and Estrogen-Receptor Status. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015; 33:2870-2876 10.1200/jco.2014.59.9191
• Breast Cancer Subtype as a Predictor of Lymph Node Metastasis according to the SEER Registry Cite
  Mattes MD, Bhatia JK, Metzger D, Ashamalla H, Katsoulakis E. Breast Cancer Subtype as a Predictor of Lymph Node Metastasis according to the SEER Registry. Journal of Breast Cancer. Korean Breast Cancer Society; 2015; 18:143 10.4048/jbc.2015.18.2.143
• Small HER2-Positive Breast Cancer: Should Size Affect Adjuvant Treatment? Cite
  Tognela A, Beith J, Kiely B, Bastick P, Lynch J, Descallar J, et al. Small HER2-Positive Breast Cancer: Should Size Affect Adjuvant Treatment?. Clinical Breast Cancer. Elsevier BV; 2015; 15:277-284 10.1016/j.clbc.2014.12.012
• Habitual sleep–wake behaviors and lifestyle as predictors of diurnal cortisol patterns in young breast cancer survivors: A longitudinal study Cite
  Hsiao F, Kuo W, Jow G, Chang K, Yang P, Lam H, et al. Habitual sleep–wake behaviors and lifestyle as predictors of diurnal cortisol patterns in young breast cancer survivors: A longitudinal study. Psychoneuroendocrinology. Elsevier BV; 2015; 53:60-68 10.1016/j.psyneuen.2014.12.014
• Invasive lobular carcinoma of the breast: long-term prognostic value of Ki67 and histological grade, alone and in combination with estrogen receptor Cite
  Narbe U, Bendahl P, Grabau D, Rydén L, Ingvar C, Fernö M. Invasive lobular carcinoma of the breast: long-term prognostic value of Ki67 and histological grade, alone and in combination with estrogen receptor. SpringerPlus. Springer Science and Business Media LLC; 2014; 3 10.1186/2193-1801-3-70
• Clinical Significance of HER2-Positive and Triple-Negative Status in Small (≤ 1 cm) Node-Negative Breast Cancer Cite
  Gorshein E, Klein P, Boolbol SK, Shao T. Clinical Significance of HER2-Positive and Triple-Negative Status in Small (≤ 1 cm) Node-Negative Breast Cancer. Clinical Breast Cancer. Elsevier BV; 2014; 14:309-314 10.1016/j.clbc.2014.02.007
• Predictors of Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From Combined Analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27 Cite
  Mamounas EP, Anderson SJ, Dignam JJ, Bear HD, Julian TB, Geyer CE, et al. Predictors of Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From Combined Analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2012; 30:3960-3966 10.1200/jco.2011.40.8369
• Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction Cite
  Kneubil M, Brollo J, Botteri E, Curigliano G, Rotmensz N, Goldhirsch A, et al. Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction. European Journal of Surgical Oncology (EJSO). Elsevier BV; 2013; 39:260-265 10.1016/j.ejso.2012.12.004
• Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients Cite
  Pogoda K, Niwińska A, Murawska M, Pieńkowski T. Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients. Medical Oncology. Springer Science and Business Media LLC; 2013; 30 10.1007/s12032-012-0388-4
• Therapeutic Mammaplasty for Breast Cancer: Oncological and Aesthetic Outcomes Cite
  Grubnik A, Benn C, Edwards G. Therapeutic Mammaplasty for Breast Cancer: Oncological and Aesthetic Outcomes. World Journal of Surgery. Springer Science and Business Media LLC; 2012; 37:72-83 10.1007/s00268-012-1786-7
• Relationship Between Mammographic Density and Breast Cancer Death in the Breast Cancer Surveillance Consortium Cite
  Gierach GL, Ichikawa L, Kerlikowske K, Brinton LA, Farhat GN, Vacek PM, et al. Relationship Between Mammographic Density and Breast Cancer Death in the Breast Cancer Surveillance Consortium. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2012; 104:1218-1227 10.1093/jnci/djs327
• Factors Associated With Local-Regional Recurrence After a Negative Sentinel Node Dissection Cite
  Hunt KK, Ballman KV, McCall LM, Boughey JC, Mittendorf EA, Cox CE, et al. Factors Associated With Local-Regional Recurrence After a Negative Sentinel Node Dissection. Annals of Surgery. Ovid Technologies (Wolters Kluwer Health); 2012; 256:428-436 10.1097/sla.0b013e3182654494
• The Impact of the Size of Nodal Metastases on Recurrence Risk in Breast Cancer Patients With 1-3 Positive Axillary Nodes After Mastectomy Cite
  Harris EE, Freilich J, Lin H, Chuong M, Acs G. The Impact of the Size of Nodal Metastases on Recurrence Risk in Breast Cancer Patients With 1-3 Positive Axillary Nodes After Mastectomy. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2013; 85:609-614 10.1016/j.ijrobp.2012.05.050
• Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer Cite
  Kim J, Han W, Moon H, Ahn SK, Shin H, You J, et al. Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer. Breast Cancer Research. Springer Science and Business Media LLC; 2012; 14 10.1186/bcr3221
• Multifocality and multicentricity in breast cancer and survival outcomes Cite
  Lynch S, Lei X, Chavez-MacGregor M, Hsu L, Meric-Bernstam F, Buchholz T, et al. Multifocality and multicentricity in breast cancer and survival outcomes. Annals of Oncology. Elsevier BV; 2012; 23:3063-3069 10.1093/annonc/mds136
• Evaluating the Feasibility of Extended Partial Mastectomy and Immediate Reduction Mammoplasty Reconstruction as an Alternative to Mastectomy Cite
  Chang EI, Peled AW, Foster RD, Lin C, Zeidler KR, Ewing CA, et al. Evaluating the Feasibility of Extended Partial Mastectomy and Immediate Reduction Mammoplasty Reconstruction as an Alternative to Mastectomy. Annals of Surgery. Ovid Technologies (Wolters Kluwer Health); 2012; 255:1151-1157 10.1097/sla.0b013e31824f9769
• Nondense mammographic area and risk of breast cancer Cite
  Pettersson A, Hankinson SE, Willett WC, Lagiou P, Trichopoulos D, Tamimi RM. Nondense mammographic area and risk of breast cancer. Breast Cancer Research. Springer Science and Business Media LLC; 2011; 13 10.1186/bcr3041
• Occult breast carcinoma in breast reduction specimens in European women Cite
  Goyal A, Coulson SG, Wu JM, Suvarna SK, Reed MWR, Caddy CM. Occult breast carcinoma in breast reduction specimens in European women. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2011; 128:749-753 10.1007/s10549-011-1589-9
• Given breast cancer, does breast size matter? Data from a prospective breast cancer cohort Cite
  Markkula A, Bromée A, Henningson M, Hietala M, Ringberg A, Ingvar C, et al. Given breast cancer, does breast size matter? Data from a prospective breast cancer cohort. Cancer Causes & Control. Springer Science and Business Media LLC; 2012; 23:1307-1316 10.1007/s10552-012-0008-9
• Invasive lobular (ILC) versus invasive ductal (IDC) breast cancer (BC): Clinical-pathologic features and clinical outcomes in monoinstitutional series. Cite
  Ferro A, Eccher C, Caldara A, Triolo R, Barbareschi M, Cuorvo LV, et al. Invasive lobular (ILC) versus invasive ductal (IDC) breast cancer (BC): Clinical-pathologic features and clinical outcomes in monoinstitutional series.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2012; 30:e21102-e21102 10.1200/jco.2012.30.15_suppl.e21102
• Vitamin D status at breast cancer diagnosis: correlation with tumor characteristics, disease outcome, and genetic determinants of vitamin D insufficiency Cite
  Hatse S, Lambrechts D, Verstuyf A, Smeets A, Brouwers B, Vandorpe T, et al. Vitamin D status at breast cancer diagnosis: correlation with tumor characteristics, disease outcome, and genetic determinants of vitamin D insufficiency. Carcinogenesis. Oxford University Press (OUP); 2012; 33:1319-1326 10.1093/carcin/bgs187
• Tumour characteristics among women with very low-risk breast cancer Cite
  Narod SA, Valentini A, Nofech-Mozes S, Sun P, Hanna W. Tumour characteristics among women with very low-risk breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2012; 134:1241-1246 10.1007/s10549-012-2065-x
• Invasive lobular breast cancer: subtypes and outcome Cite
  Iorfida M, Maiorano E, Orvieto E, Maisonneuve P, Bottiglieri L, Rotmensz N, et al. Invasive lobular breast cancer: subtypes and outcome. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2012; 133:713-723 10.1007/s10549-012-2002-z
• Analysis of Clinical Features and Outcome of 356 Triple-Negative Breast Cancer Patients in China Cite
  Zhang L, Hao C, Dong G, Tong Z. Analysis of Clinical Features and Outcome of 356 Triple-Negative Breast Cancer Patients in China. Breast Care. S. Karger AG; 2012; 7:13-17 10.1159/000336539
• S4-6: A Quantitative Multigene RT-PCR Assay for Predicting Recurrence Risk after Surgical Excision Alone without Irradiation for Ductal Carcinoma In Situ (DCIS): A Prospective Validation Study of the DCIS Score from ECOG E5194. Cite
  Solin L, Gray R, Baehner F, Butler S, Badve S, Yoshizawa C, et al. S4-6: A Quantitative Multigene RT-PCR Assay for Predicting Recurrence Risk after Surgical Excision Alone without Irradiation for Ductal Carcinoma In Situ (DCIS): A Prospective Validation Study of the DCIS Score from ECOG E5194.. General Session Abstracts. American Association for Cancer Research; 2011; 10.1158/0008-5472.sabcs11-s4-6
• Should palpable DCIS be treated as IDC? A retrospective audit. Cite
  Nair NS, Pandey N, Vanmali V, Shet T, Hawaldar R, Parmar V, et al. Should palpable DCIS be treated as IDC? A retrospective audit.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:146-146 10.1200/jco.2011.29.27_suppl.146
• Association between race and BMI with response to neoadjuvant endocrine therapy in postmenopausal women with large estrogen receptor-positive breast cancers. Cite
  Ambros T, Sujoy V, Fernandez CG, Reis I, Wright JL, Jorda M, et al. Association between race and BMI with response to neoadjuvant endocrine therapy in postmenopausal women with large estrogen receptor-positive breast cancers.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:132-132 10.1200/jco.2011.29.27_suppl.132
• Triple-Negative Breast Cancer Is Not a Contraindication for Breast Conservation Cite
  Adkins FC, Gonzalez-Angulo AM, Lei X, Hernandez-Aya LF, Mittendorf EA, Litton JK, et al. Triple-Negative Breast Cancer Is Not a Contraindication for Breast Conservation. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2011; 18:3164-3173 10.1245/s10434-011-1920-z
• Prognostic impact of isolated tumor cells in breast cancer axillary nodes: single tumor cell(s) versus tumor cell cluster(s) and microanatomic location Cite
  Vestjens JH, de Boer M, van Diest PJ, van Deurzen CH, van Dijck JA, Borm GF, et al. Prognostic impact of isolated tumor cells in breast cancer axillary nodes: single tumor cell(s) versus tumor cell cluster(s) and microanatomic location. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2011; 131:645-651 10.1007/s10549-011-1771-0
• Lobular Breast Cancer: Same Survival and Local Control Compared with Ductal Cancer, but Should Both Be Treated the Same Way? Analysis of an Institutional Database over a 10-Year Period Cite
  Fortunato L, Mascaro A, Poccia I, Andrich R, Amini M, Costarelli L, et al. Lobular Breast Cancer: Same Survival and Local Control Compared with Ductal Cancer, but Should Both Be Treated the Same Way? Analysis of an Institutional Database over a 10-Year Period. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2011; 19:1107-1114 10.1245/s10434-011-1907-9
• Comparison of locoregional recurrence in triple-negative and HER2-positive breast cancer subtype after breast-conserving therapy and modern systemic therapy. Cite
  Takita C, Reis IM, Miao F, LaFave KE, Gunaseelan V, Hurley J, et al. Comparison of locoregional recurrence in triple-negative and HER2-positive breast cancer subtype after breast-conserving therapy and modern systemic therapy.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:112-112 10.1200/jco.2011.29.27_suppl.112
• Occult axillary lymph node metastases do not have prognostic significance in early stage breast cancer Cite
  Wu Y, Mittendorf EA, Kelten C, Tucker SL, Wei W, Middleton LP, et al. Occult axillary lymph node metastases do not have prognostic significance in early stage breast cancer. Cancer. Wiley; 2011; 118:1507-1514 10.1002/cncr.26458
• Is breast-conserving therapy a safe option for patients with tumor multicentricity and multifocality? Cite
  Yerushalmi R, Tyldesley S, Woods R, Kennecke H, Speers C, Gelmon K. Is breast-conserving therapy a safe option for patients with tumor multicentricity and multifocality?. Annals of Oncology. Elsevier BV; 2011; 23:876-881 10.1093/annonc/mdr326
• Mammographic Breast Density and Subsequent Risk of Breast Cancer in Postmenopausal Women According to Tumor Characteristics Cite
  Yaghjyan L, Colditz GA, Collins LC, Schnitt SJ, Rosner B, Vachon C, et al. Mammographic Breast Density and Subsequent Risk of Breast Cancer in Postmenopausal Women According to Tumor Characteristics. JNCI Journal of the National Cancer Institute. Oxford University Press (OUP); 2011; 103:1179-1189 10.1093/jnci/djr225
• Breast cancer multifocality, disease extent, and survival Cite
  Tot T, Gere M, Pekár G, Tarján M, Hofmeyer S, Hellberg D, et al. Breast cancer multifocality, disease extent, and survival. Human Pathology. Elsevier BV; 2011; 42:1761-1769 10.1016/j.humpath.2011.02.002
• Clear margins for invasive lobular carcinoma: A surgical challenge Cite
  Sakr R, Poulet B, Kaufman G, Nos C, Clough K. Clear margins for invasive lobular carcinoma: A surgical challenge. European Journal of Surgical Oncology (EJSO). Elsevier BV; 2011; 37:350-356 10.1016/j.ejso.2011.01.010
• Biologic markers determine both the risk and the timing of recurrence in breast cancer Cite
  Esserman LJ, Moore DH, Tsing PJ, Chu PW, Yau C, Ozanne E, et al. Biologic markers determine both the risk and the timing of recurrence in breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2011; 129:607-616 10.1007/s10549-011-1564-5
• Nodal Status and Clinical Outcomes in a Large Cohort of Patients With Triple-Negative Breast Cancer Cite
  Hernandez-Aya LF, Chavez-MacGregor M, Lei X, Meric-Bernstam F, Buchholz TA, Hsu L, et al. Nodal Status and Clinical Outcomes in a Large Cohort of Patients With Triple-Negative Breast Cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:2628-2634 10.1200/jco.2010.32.1877
• Prognostic significance of triple negative breast cancer at tumor size 1 cm and smaller Cite
  Lai H, Kuo S, Chen L, Chi C, Chen S, Chang T, et al. Prognostic significance of triple negative breast cancer at tumor size 1 cm and smaller. European Journal of Surgical Oncology (EJSO). Elsevier BV; 2011; 37:18-24 10.1016/j.ejso.2010.10.003
• Prognosis and Outcome of Small (≤1 cm), Node‐Negative Breast Cancer on the Basis of Hormonal and HER‐2 Status Cite
  Amar S, McCullough AE, Tan W, Geiger XJ, Boughey JC, McNeil RB, et al. Prognosis and Outcome of Small (≤1 cm), Node‐Negative Breast Cancer on the Basis of Hormonal and HER‐2 Status. The Oncologist. Wiley; 2010; 15:1043-1049 10.1634/theoncologist.2010-0036
• Prognosis and pathology of screen-detected carcinomas Cite
  Nagtegaal ID, Allgood PC, Duffy SW, Kearins O, Sullivan EO, Tappenden N, et al. Prognosis and pathology of screen-detected carcinomas. Cancer. Wiley; 2010; 117:1360-1368 10.1002/cncr.25613
• Prognosis of medullary breast cancer: Analyses of 13 International Breast Cancer Study Group (IBCSG) trials. Cite
  Huober JB, Gelber S, Thürlimann B, Regan MM, Price KN, Goldhirsch A, et al. Prognosis of medullary breast cancer: Analyses of 13 International Breast Cancer Study Group (IBCSG) trials.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:630-630 10.1200/jco.2010.28.15_suppl.630
• Multifocality as a prognostic factor in breast cancer patients registered in Danish Breast Cancer Cooperative Group (DBCG) 1996–2001 Cite
  Joergensen L, Gunnarsdottir K, Lanng C, Moeller S, Rasmussen B. Multifocality as a prognostic factor in breast cancer patients registered in Danish Breast Cancer Cooperative Group (DBCG) 1996–2001. The Breast. Elsevier BV; 2008; 17:587-591 10.1016/j.breast.2008.06.004
• Does multicentric/multifocal breast cancer differ from unifocal breast cancer? An analysis of survival and contralateral breast cancer incidence Cite
  Yerushalmi R, Kennecke H, Woods R, Olivotto IA, Speers C, Gelmon KA. Does multicentric/multifocal breast cancer differ from unifocal breast cancer? An analysis of survival and contralateral breast cancer incidence. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2008; 117:365-370 10.1007/s10549-008-0265-1
• Conservative surgery in patients with multifocal/multicentric breast cancer Cite
  Gentilini O, Botteri E, Rotmensz N, Da Lima L, Caliskan M, Garcia-Etienne CA, et al. Conservative surgery in patients with multifocal/multicentric breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2008; 113:577-583 10.1007/s10549-008-9959-7
• Multicentric and multifocal versus unifocal breast cancer: is the tumor-node-metastasis classification justified? Cite
  Weissenbacher TM, Zschage M, Janni W, Jeschke U, Dimpfl T, Mayr D, et al. Multicentric and multifocal versus unifocal breast cancer: is the tumor-node-metastasis classification justified?. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2010; 122:27-34 10.1007/s10549-010-0917-9
• Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer Cite
  Wong H, Lau S, Yau T, Cheung P, Epstein RJ. Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer. British Journal of Cancer. Springer Science and Business Media LLC; 2010; 102:1391-1396 10.1038/sj.bjc.6605655
• Locoregional recurrence after breast-conserving therapy remains an independent prognostic factor even after an event free interval of 10years in early stage breast cancer Cite
  Tanis E, van de Velde C, Bartelink H, van de Vijver M, Putter H, van der Hage J. Locoregional recurrence after breast-conserving therapy remains an independent prognostic factor even after an event free interval of 10years in early stage breast cancer. European Journal of Cancer. Elsevier BV; 2012; 48:1751-1756 10.1016/j.ejca.2012.02.051
• Breast cancer in women under 40 years of age: A series of 57 cases from Northern Ireland Cite
  McAree B, O'Donnell M, Spence A, Lioe T, McManus D, Spence R. Breast cancer in women under 40 years of age: A series of 57 cases from Northern Ireland. The Breast. Elsevier BV; 2010; 19:97-104 10.1016/j.breast.2009.12.002
• Ductal Carcinoma In Situ of the Breast: A Systematic Review of Incidence, Treatment, and Outcomes Cite
  Virnig BA, Tuttle TM, Shamliyan T, Kane RL. Ductal Carcinoma In Situ of the Breast: A Systematic Review of Incidence, Treatment, and Outcomes. JNCI Journal of the National Cancer Institute. Oxford University Press (OUP); 2010; 102:170-178 10.1093/jnci/djp482
• A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma Cite
  Di Saverio S, Gutierrez J, Avisar E. A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2007; 111:541-547 10.1007/s10549-007-9809-z
• Combination of methylselenocysteine with tamoxifen inhibits MCF-7 breast cancer xenografts in nude mice through elevated apoptosis and reduced angiogenesis Cite
  Li Z, Carrier L, Belame A, Thiyagarajah A, Salvo VA, Burow ME, et al. Combination of methylselenocysteine with tamoxifen inhibits MCF-7 breast cancer xenografts in nude mice through elevated apoptosis and reduced angiogenesis. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2008; 118:33-43 10.1007/s10549-008-0216-x
• Suppression of Implanted MDA-MB 231 Human Breast Cancer Growth in Nude Mice by Dietary Walnut Cite
  Hardman WE, Ion G. Suppression of Implanted MDA-MB 231 Human Breast Cancer Growth in Nude Mice by Dietary Walnut. Nutrition and Cancer. Informa UK Limited; 2008; 60:666-674 10.1080/01635580802065302